CSBR
Champions Oncology, Inc. NASDAQ Listed Feb 2, 2007$6.13
-4.67%
vs $6.43
Mkt Cap $85.1M
52w Low $5.50
15.3% of range
52w High $9.63
50d MA $6.05
200d MA $6.38
P/E (TTM)
—
EV/EBITDA
—
P/B
22.2x
Debt/Equity
1.6x
ROE
-1.7%
P/FCF
12.5x
RSI (14)
62.20
ATR (14)
$0.50
Beta
0.40
50d MA
$6.05
200d MA
$6.38
Avg Volume
8.4K
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
One University Plaza · Hackensack, NJ 07601 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | 0.09 | -0.02 | -122.2% | 5.74 | -4.0% | +6.3% | +2.5% | -0.8% | -6.0% | +6.3% | — |
| Dec 15, 2025 | AMC | 0.08 | 0.02 | -75.0% | 7.80 | -0.1% | -13.7% | -6.1% | +14.2% | +0.0% | +0.4% | — |
| Sep 15, 2025 | AMC | 0.01 | -0.03 | -400.0% | 8.30 | -16.6% | -16.0% | -8.9% | +5.5% | -1.9% | +2.7% | — |
| Jul 23, 2025 | AMC | 0.06 | -0.13 | -316.7% | 7.75 | -12.9% | -14.2% | -6.2% | +1.0% | +1.9% | -0.2% | — |
| Mar 11, 2025 | AMC | -0.01 | 0.31 | +3200.0% | 9.79 | +2.1% | -2.5% | -6.9% | +3.8% | +10.0% | -5.3% | — |
| Dec 11, 2024 | AMC | 0.01 | 0.05 | +400.0% | 5.84 | +6.7% | -11.6% | +22.7% | -1.3% | +2.4% | +8.0% | — |
| Sep 11, 2024 | AMC | 0.02 | 0.11 | +466.8% | 4.07 | +15.5% | +9.6% | +13.2% | -1.0% | -8.0% | -7.0% | — |
| Jul 18, 2024 | AMC | -0.16 | -0.01 | +93.8% | 4.92 | +4.9% | +2.6% | +0.0% | -3.0% | -2.2% | +0.4% | — |
| Mar 12, 2024 | AMC | -0.06 | -0.19 | -216.7% | 5.67 | -9.2% | -3.0% | -1.6% | +1.1% | -4.6% | -2.3% | — |
| Dec 12, 2023 | AMC | -0.17 | -0.15 | +11.8% | 4.61 | +2.8% | +5.4% | -1.6% | -3.6% | +0.4% | -1.5% | — |
| Sep 13, 2023 | AMC | -0.10 | -0.19 | -90.0% | 5.50 | -1.3% | -1.5% | -3.1% | -1.0% | +0.2% | +2.7% | — |
| Jul 24, 2023 | AMC | -0.12 | -0.19 | -58.3% | 6.41 | +4.7% | +0.0% | +0.2% | +0.8% | +0.2% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Craig-Hallum | Maintains | Buy → Buy | — | $9.79 | $10.00 | +2.1% | -2.5% | -6.9% | +3.8% | +10.0% | -5.3% |
| Dec 12 | Craig-Hallum | Maintains | Buy → Buy | — | $5.84 | $6.23 | +6.7% | -11.6% | +22.7% | -1.3% | +2.4% | +8.0% |
| Sep 12 | Craig-Hallum | Upgrade | Hold → Buy | — | $4.07 | $4.70 | +15.5% | +9.6% | +13.2% | -1.0% | -8.0% | -7.0% |
| Mar 13 | Craig-Hallum | Downgrade | Buy → Hold | — | $5.67 | $5.15 | -9.2% | -3.0% | -1.6% | +1.1% | -4.6% | -2.3% |
| Sep 22 | Roth MKM | Maintains | Buy → Buy | — | $5.33 | $5.42 | +1.7% | +1.3% | +0.2% | +4.4% | +2.3% | +5.2% |
| Mar 15 | Roth Capital | Maintains | Buy → Buy | — | $11.89 | $11.86 | -0.3% | +15.3% | +0.3% | -9.2% | +5.7% | -5.5% |
| Nov 18 | Benchmark | Maintains | Speculative Buy → Buy | — | $5.39 | $5.54 | +2.8% | -5.0% | +1.6% | +5.2% | -0.9% | +1.3% |
| Sep 20 | Roth Capital | Maintains | Buy → Buy | — | $6.08 | $6.24 | +2.6% | -1.3% | -0.3% | -1.7% | -3.2% | -0.2% |
| Jul 24 | Janney Capital | Downgrade | Buy → Neutral | — | $7.21 | $7.00 | -2.9% | -1.5% | -2.8% | +0.1% | -4.1% | -0.2% |
| Jul 24 | Janney Montgomery Scott | Downgrade | Buy → Neutral | — | $7.21 | $7.00 | -2.9% | -1.5% | -2.8% | +0.1% | -4.1% | -0.2% |
| Jul 17 | Craig-Hallum | Maintains | Buy → Buy | — | $5.82 | $6.00 | +3.1% | +25.4% | +13.2% | +7.6% | -1.5% | -0.7% |
| May 15 | Dawson James | Maintains | Buy → Buy | — | $4.25 | $4.45 | +4.7% | -2.1% | +0.2% | +0.2% | +0.0% | -0.5% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The executive's dual role as CEO-Partner at Flagship Pioneering since November 2024 may indicate divided attention and potential governance concerns, risking strategic focus and investor confidence in CSBR's leadership.
Mar 30
8-K
Unknown — 8-K Filing
Champions Oncology achieved positive adjusted EBITDA in Q3 FY2026, signaling the company has reached profitability on an operational basis, which validates its business model and may support stock appreciation.
Mar 12
Institutional (13F) — Top 15
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Battery Management Corp. | 2,421,673 | $14M | — | Mar 2026 |
| 2 | Morgan Stanley | 459,318 | $3M | Added | Dec 2025 |
| 3 | Tocqueville Asset Management L.p. | 319,674 | $2M | — | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 299,520 | $2M | New | Mar 2026 |
| 5 | Renaissance Technologies Llc | 145,539 | $837K | Reduced | Mar 2026 |
| 6 | Mink Brook Asset Management Llc | 111,338 | $640K | Added | Mar 2026 |
| 7 | Northern Trust Corp | 45,932 | $264K | — | Mar 2026 |
| 8 | Hightower Advisors, Llc | 35,158 | $243K | — | Dec 2025 |
| 9 | Bank Of America Corp /de/ | 21,833 | $126K | — | Mar 2026 |
| 10 | Bank Of New York Mellon Corp | 21,614 | $124K | Reduced | Mar 2026 |
| 11 | Acadian Asset Management Llc | 21,323 | $121K | Reduced | Mar 2026 |
| 12 | Essex Investment Management Co Llc | 18,249 | $105K | — | Mar 2026 |
| 13 | Mesirow Financial Investment Management, Inc. | 15,800 | $91K | Added | Mar 2026 |
| 14 | Jpmorgan Chase & Co | 11 | $64 | — | Mar 2026 |
| 15 | Capital Advisors, Ltd. Llc | 48 | — | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 15
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 31,801 | $191K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 22,550 | $130K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 12,140 | $73K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 10,958 | $66K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 8,688 | $52K | Feb 2026 |
| 6 | Schwab Total Stock Market Index Fund | 6,854 | $50K | Jan 2026 |
| 7 | Small Cap Core Fund | 4,883 | $28K | Mar 2026 |
| 8 | U.S. Social Core Equity 2 Portfolio | 2,279 | $17K | Jan 2026 |
| 9 | U.S. CORE EQUITY 2 PORTFOLIO | 1,764 | $13K | Jan 2026 |
| 10 | Dimensional US Core Equity 1 ETF | 1,719 | $13K | Jan 2026 |
| 11 | U.S. CORE EQUITY 1 PORTFOLIO | 1,709 | $12K | Jan 2026 |
| 12 | U.S. Sustainability Core 1 Portfolio | 1,220 | $9K | Jan 2026 |
| 13 | LVIP Dimensional U.S. Core Equity 2 Fund | 1,317 | $8K | Mar 2026 |
| 14 | U.S. VECTOR EQUITY PORTFOLIO | 409 | $3K | Jan 2026 |
| 15 | Dimensional US Sustainability Core 1 ETF | 201 | $1K | Jan 2026 |
Valuation
Market Cap
$85.1M
Enterprise Value
$82.0M
P/E (TTM)
—
Forward P/E
61.30x
PEG Ratio
-0.13x
P/B
22.20x
P/S
1.51x
P/FCF
12.50x
EV/EBITDA
—
Shares Out
14.3M
Financials (TTM)
Revenue
$57.9M
Net Income
-$2.3M
EBITDA
-$948K
Free Cash Flow
$7.0M
Op Cash Flow
$7.4M
EPS Basic
$0.34
EPS Diluted
$-0.16
EPS Forward
$0.10
Gross Margin
45.9%
Op Margin
-3.8%
Net Margin
-3.9%
Balance Sheet
Total Assets
$32.3M
Total Liab.
$28.6M
Total Equity
$3.8M
Cash
$9.8M
LT Debt
$0
Book Value/Sh
$0.28
Debt/Equity
1.62x
Current Ratio
0.94
Quick Ratio
0.94
Returns & Growth
ROE
-1.7%
ROA
-0.3%
ROIC
48.6%
Rev Growth YoY
+13.5%
EPS Growth YoY
+163.0%
Price Returns
2W
-1.1%
1M
+10.1%
3M
+10.1%
6M
-1.8%
12M
-12.8%
Technicals
52W High
$9.63
52W Low
$5.50
50d MA
$6.05
200d MA
$6.38
RSI (14)
62.20
ATR (14)
$0.50
Beta
0.40
Avg Volume
8K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 25, 2026 3:28am
· Source: financialmodelingprep.com